Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of the H5-VLP + GLA-AF Pandemic Influenza Vaccine in Healthy Adult Subjects

Next Previous
Trial Profile

A Phase 1, Randomized Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of the H5-VLP + GLA-AF Pandemic Influenza Vaccine in Healthy Adult Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 02 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MT-8972 (Primary) ; MT-8972 (Primary) ; Aluminium hydroxide; Glycopyranosyl lipid adjuvant; Glycopyranosyl lipid adjuvant
  • Indications Influenza A virus H5N1 subtype
  • Focus Adverse reactions

Most Recent Events

  • 18 Feb 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
  • 17 Apr 2013 Interim results published in a Medicago media release and presented at the World Vaccine Congress.
  • 09 Apr 2013 Positive interim results will be presented at the World Vaccine Congress.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top